Latest addition to Company’s genomic testing services menu delivers rapid results to physicians that inform clinical management and outcomes for critically ill patients WALTHAM, Mass. – May 16, 2022 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the availability of ultrarapid whole genome sequencing (urWGS) through PerkinElmer Genomics.... Read more
Consortium aims to speed the development and delivery of customized or ‘bespoke’ gene therapies WASHINGTON, May 12, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it has joined the Bespoke Gene Therapy Consortium (BGTC). Launched in October 2021, the BGTC will generate gene therapy resources that the research community can use to streamline gene... Read more
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18 Company... Read more
Mining crystals is a filthy business, from poisoning drinking water to destroying ecosystems and being tied to grave human rights violations. This billion-dollar company based on a new-age fad has a significant environmental and human footprint. Before you invest in a healing gemstone, which many celebrities such as Gwyneth Paltrow, the Olsen twins, and Marie... Read more
WASHINGTON, May 4, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 11, 2022 at 10:00 a.m. PT. The audio will be simultaneously webcast on www.danaher.com. ABOUT DANAHERDanaher... Read more
Continuing strong underlying demand: Organic orders growth of 14%, up 12% on a reported basis Revenue of $1.3 billion, up 1% on a reported basis, up 4% organically Earnings per share $0.45; adjusted earnings per share $0.47 Raising full-year organic revenue guidance to a range of 4% to 6%, and adjusted earnings per share to... Read more
First quarter revenue of $1.26 billion First quarter GAAP EPS from continuing operations of $1.40; Adjusted EPS of $2.41 Initiates Second Quarter and Raises Full Year Guidance WALTHAM, Mass.–(BUSINESS WIRE)–May 3, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended... Read more
Innovations and expertise centered on accelerating therapeutic and personalized medicine R&D WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, is participating at the Bio-IT World Conference and Expo, May 3-5, in Boston, MA (booths #908, #912), with a focus on helping labs make well-informed and timely data-driven decisions on therapeutic... Read more
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 2, 2022. First Quarter 2022 Highlights First quarter revenue was $11.82 billion. First quarter GAAP diluted earnings per share (EPS) was $5.61. First quarter adjusted EPS was $7.25. Delivered... Read more
New FluoroType® Mycobacteria PCR assay detects the mycobacteria complex and differentiates 32 clinically relevant mycobacteria species from culture, using LiquidArray® multiplex PCR technology* New FluoroType® STI PCR assay detects seven major pathogens causing Sexually Transmitted Infections (STIs), using LiquidArray® multiplex PCR technology* New MBT Compass HT IVD software provides significantly increased speed for microbial identification... Read more